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A network pharmacology and in vivo research approach to evaluating the
distinction and efﬁcacy of Shenfu and Shenmai injection
Li Pan, Lv Bin, Wang Ting, Jiang Xiaoqing, Gao Xiumei, Wang Xiaoying
Tianjin University of Traditional Chinese Medicine, Tianjin, China
Objectives: Shenfu and Shenmai injection (SFI and SMI) are both Traditional
Chinese Medicine prescriptions, which are constituted by Renshen (Panax ginseng)
with Fuzi (Radix Aconiti Carmichaeliare) and Maidong (Radix Ophiopogonis)
respectively. Both of them are widely used in the treatment of cardiovascular
diseases, such as cardiac ischemia, heart failure and arrhythmia. Although the
different constitutions of the two injections were proved to have different effects,
the distinction between SFI and SMI is not clear, especially on the targets and
molecular mechanism, which has already lead to misuse in clinic. Thus, a system
research of SFI and SMI should be processed to clarify the characteristics, potential
targets and pathways to provide theoretical basis for the clinical standard
medication.
Methods: The active ingredients of SFI and SMI were identiﬁed by UPLC-q/TOF-MS
method. Brieﬂy, the separation of the sample was performed on a Waters Acquity
UPLC BEH C18 column with a column temperature maintained at 30C. UV
detection was performed over the range of 190-400 nm. By making 3D chemical
structural formulas of the active ingredients with ChemBioDraw, a network phar-
macological investigation was proceeded to deﬁnite the potential targets and path-
ways. The chemical structural formulas were submitted into a docking database
PharmMapper, subsequently with being annotated and analyzed with Kyoto Ency-
clopedia of Genes and Genomes (KEGG) and imported into Molecule Annotation
System to obtain target proteins and cardiovascular-related pathways. To verify and
evaluate the impact of SFI and SMI, an in vivo experiment was carried out on
endothelial nitric oxide synthase knockout (eNOS-KO) mice by echocardiography in
Vevo 2100 ultrasound system.
Results: With UPLC-q/TOF-MS, in SFI, ginsenosides such as Rg1, Rb1, Rb2 and
Rb3 were identiﬁed, 4 kinds of single type of aconitines were veriﬁed. In SMI there
are 19 types of Saponin, including 20 (S)-Ginsenoside Rg2, Ro, Ra2 and Ra1.
To forecast and analyze the potential targets and pathways, the chemical compo-
sitions of SFI and SMI were imported in PharmMapper to dock. A total of 385 targets
from SFI and 303 targets from SMI were obtained. These targets were annotated by
KEGG, and get a result of 66 pathways from SFI, and 60 pathways from SMI. On the
top 5 pathways in cardiovascular-related pathways of SFI are T cell receptor signaling
pathway, VEGF signaling pathway, Focal adhesion, Drug metabolism - cytochrome
P450, and MAPK signaling pathway. Top 5 pathways of SMI are Focal adhesion,
PPAR signaling pathway, Regulation of actin cytoskeleton, VEGF signaling pathway,
and Drug metabolism - cytochrome P450. Different pathways of the two injections
showed a better effect of SMI of anti-inﬂammation and SFI on anti-apoptosis. Left
ventricular function was detected on 0, 7 and 14 d after SFI or SMI intraperitoneal
administration. Ejection fraction, fractional shortening, end-systolic dimension, end-
diastolic volume and the blood ﬂow of aorta were signiﬁcantly improved by SMI on
the 7th day, whereas SFI was more efﬁcient on the 14th day which might due to anti-
apoptosis effect.
Conclusions: This study indicated that both SFI and SMI has protective effects
against cardiac dysfunction, while SMI is beneﬁt on anti-inﬂammation in the early
stage, and SFI on anti-apoptosis in the late stage of heart injury. The construction of
multi-component-multi-target network of SFI and SMI may provide a rational basis
for further research and for clinical use.
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A novel hydrogen sulﬁde-nitric oxide-releasing hybrid (HSNO) in stimulation of
angiogenesis: new insights into the biology of hydrogen sulﬁde and nitric oxide
Hu Qingxun, Wu Dan, Gu Xianfeng, Zhu Yizhun
Department of Pharmacology, School of Pharmacy, Fudan University
Objectives: Angiogenesis is a complex process of extracellular matrix remodeling
and changing, in which endothelial cells (ECs) play an important role. In endothelial
cells, hydrogen sulﬁde (H2S) and nitric oxide (NO) are synthesized respectively by
cystathionine g-lyase (CSE) and the endothelial isoform of NO synthase (eNOS).
Growing evidence has suggested that H2S and NO are important regulators of cell
angiogenesis. However, it is hardly conclusive that whether H2S and NO react
together better or not. Herein, we synthesize a novel hydrogen sulﬁde-nitric oxide-
releasing hybrid (HSNO) with H2S donor and NO donor. This hybrid is used as
a tool to unravel the mystery and investigate the cardiovascular biology of
these gases.
Methods: The novel hybrid was developed by H2S donor coupled with NO donor.
Cell viability and p53 expression were determined to assess cellular toxicity. The
releases of H2S and NO from HSNO were measured via the spectrometer assay.JACC Vol 64/16/Suppl C j October 16–19, 2014 j GW-ICC Abstracts/OAngiogenesis was assessed using in vitro parameters (i.e. endothelial cell prolifera-
tion, transwell migration assay and formation of tube-like structure) and in vivo by
matrigel plug assay and aortic ring assay. Cyclic guanosine 5’-monophosphate
(cGMP) content in cell was measured by enzyme-linked immunosorbent assay.
Western blot was used to determine the expression levels of proteins.
Results: Treatment of ECs with HSNO did not cause signiﬁcant cytotoxicity or
apoptosis. HSNO released H2S and NO slowly after administration in vivo. HSNO
concentration-dependently accelerated cell growth, migration and tube-like structure
formation ex vivo and in vivo. At the same concentration, the hybrid was more potent
than either one alone. These effects of HSNO on cell proliferation and migration were
prevented by PI3K inhibitor LY294002, ERK inhibitor UO126 and p38 inhibitor
SB203580. Incubation of ECs with HSNO resulted in the increase of phosphorylation
of PI3K, Akt, ERK and p38, and these effects could be blocked by respective
inhibitors. HSNO increased the content of cGMP and activated protein kinase G
(PKG) as well as its downstream effectors.
Conclusions: The present study proves that H2S and NO react together much potent
than either one alone in cell proliferation. As a slow-releasing H2S and NO hybrid,
HSNO is a useful tool to study the interactions between H2S and NO in many bio-
logical effects. Moreover HSNO could be recognized as an important potential drug in
the therapy of cardiovascular disease.
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The Research of Evaluation Standard of curative effect of coronary heart disease
angina Based on clinical literature
Li Yanyang1, Zhong Aiqin1, Zhu Yaping2, Zhang Junping2
1Tianjin University of Chinese Medicine, 2The First Hospital Afﬁliated to Tianjin
University of Chinese Medicine
Objectives: To explore the efﬁcacy evaluation system of CHD angina, we adjust
problems of CHD angina combing the efﬁcacy evaluation according to studying
literature.
Methods: Using the method of clinical literature of CHD angina based on research
objectives of CHD angina literature to summarize and extract the data of evaluation
standard of curative effect, and provide ideas for establishing the clinical efﬁcacy
evaluation system of CHD angina.
Results: Association of International Medicine Economics and Efﬁcacy, Coordi-
nation Ofﬁce of the Quality evaluation in Europe, Food and Drug Administration in
US, Working Group of healthy related quality of life and Administration, Interna-
tional surviving quality who call on the evaluation method of clinical effect include
the function assessment, indicators of physical chemistry, report of caregivers and
result indicators of patients report from doctor. In general the efﬁcacy evaluation of
CHD angina can be divided into the following categories: Firstly, Biochemical
indicators such as lipids, C-reactive protein, troponin, NO, superoxide dismutase,
lipid peroxidation, tumor necrosis factor-a, interleukin-1, interleukin-6 and so on.
Secondly, ECG indicators such as 24-hour ambulatory ECG and treadmill exercise
testing. Thirdly, Radiographic indicators such as coronary angiography, intra-
vascular ultrasound (IVUS), X-ray computer tomography (CT), magnetic re-
sonance imaging Heart (CMR) and so on. Fourthly, Symptom evaluation is patients
classiﬁcation symptoms which give scores such as symptom score sheets and
other quality of life scales. Fifthly, result indicators, including in the incidence of
cardiovascular events (myocardial infarction, sudden cardiac death) and the hospi-
talizations per year. Finally, evaluation indicators which reﬂect on Chinese medi-
cine, table of accumulation symptom which is not complicated nowadays, but it
offer a basic theory to build evaluation method of curative effect and standard
system.
Conclusions: On one hand, we should clear the purpose of each indicators and do the
best choice in scope of clinical indicators for curative effect evaluation of CHD
angina. On the other hand, we should pay a attention to the structure and hierarchy to
be sure the weight and relation of each indicators and build a synthetical evaluation
method in clinical indicators system.
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One case of coronary angiography in patients with orthotopic heart
transplantation 10 years
Wang Mengxiao, Yang Xiuchun, Lu Jingchao, Li Yue, Liu Fan
The Secong Hospital of Hebei Medical University
Objectives: Male, 41 years old, accepted heart transplantation in our hospital 10
years ago due to dilated cardiomyopathy, heart failure. The patient came to
hospital because of palpitations for 1 day. Physical examination: T 36.4C, P 38/
min, R 16/min, BP 131/68 mmHg, His consciousness was clear. No abnormal breath
sound was heard. Heart rate 38/min. Cardiac rhythm was not regular. No patho-
logical murmurs.More than physical examination did not see obvious anomalies.
The result of the holter: Sinus rhythm, paroxysmal atrial ﬁbrillation, advanced
or three degree atrioventricular block, average heart rate is 76 bpm, the slowest is
35 bpm, the fasted is 113 bpm, the amount of more than 2 seconds long pause
is 175.
Methods: The diagnosis of the patient was dilated cardiomyopathy, heart failure,
NYHA class IV, post of heart transplantation, atrial ﬁbrillation, three degree atrio-
ventricular block.
Results: We used all kinds of drugs to improve the patient’s heart rate, but there was
no effect. So we decided to implante a cardiac pacemaker (DDD). In order tothers C239
